Treatment of Major Depression

External reference: https://openalex.org/T11071

  1. Molecular imaging links late-life depression to neurotransmitter and Alzheimer’s changes
    Molecular imaging reveals late-life depression involves altered neurotransmitter systems, Alzheimer's pathology, and neuroinflammation, supporting development of targeted mechanism-based treatments.
  2. Zuranolone was approved for postpartum depression, not major depressive disorder
    Analysis of zuranolone approval reveals how fast-track designations and reduced evidentiary thresholds in drug regulation may inadequately balance innovation with public health protection.
  3. Dysfunctional metacognitive beliefs may contribute to interpersonal distress
    Longitudinal study shows dysfunctional metacognitive beliefs predict interpersonal distress trajectories independent of parental bonds, interpersonal style, depression and anxiety, suggesting new.
  4. Reasoning-based LLMs may predict antidepressant response
    Study evaluates reasoning-based large language models for predicting 12-week remission in depressive disorder patients undergoing antidepressant monotherapy.
  5. CBT outcomes linked more to sessions attended than session rate
    Observational primary-care CBT analysis: higher baseline severity linked to greater absolute symptom reduction; total session count, not attendance rate, predicts outcomes; waiting time showed no.